Update in Medical Retinal Treatments and Lasers
At Clinica London, our consultants assess and treat patients with medical retinal diseases. They use new drugs and biologics as part of their medical retinal treatments. In the future, there will also be powerful rejuvenating retinal lasers.
The global retinal drugs and biologics market is driven by the need for advanced and new treatment of age-related macular degeneration, diabetic retinopathy, ocular inflammatory disease (uveitis) and macular hole. There are many other retinal conditions, which can benefit from the new drugs that are becoming available. Most commonly these drugs are administered by intravitreal injection by the medical retina ophthalmic specialist. The medicines include anti-VEGF drugs such as:
There is also intravitreal implant releasing steroids such as Dexamethasone and Fluocinolone.
Epidemiological studies have shown that there are over 296 million people worldwide who suffer from some form of medical retina disease or condition. Around 142 million people of these have age-related macular degeneration, and 105 million are affected by diabetic eye disease.
This makes age-related macular degeneration and diabetic eye disease in combination the leading causes of vision loss globally. Both of which could be almost preventable diseases, but currently form a large part of the medical retinal specialists’ daily workload.
Retinal drugs and biologics are going to help people with retinal disease to retain their vision and even improve their vision. Together with drug and biologics treatment, the importance of lifestyle is being stressed to help prevent retinal disease, via stopping smoking, exercise, diet and control of medical conditions such as hypertension and diabetes. Unfortunately, the growing incidence of diabetes in developed countries due to an adopted sedentary lifestyle and unhealthy eating and smoking habits is likely to make retinal disease more prevalent in those Asia Pacific countries and their need for medical retinal treatments and biologics higher.
Meanwhile, in developed countries, we see good responses to intravitreal anti-VEGFs, biologics and improved lifestyle. In the future, we look forward to retinal rejuvenation with such lasers as Ellex Retinal Rejuvenation Therapy (Ellex 2RT™) which is a breakthrough laser therapy which has the potential to influence the lives of millions of people positively. This is still at the trial stage and only available to date at a couple of centres in London and is still very expensive.
We are fortunate to have two retinal specialists at Clinica London. Professor Michel Michaelides is a Professor at the UCL Institute of Ophthalmology and Moorfields Eye Hospital. Mr Jaheed Khan is a consultant medical retinal specialist at Moorfields Eye Hospital. Both assess patients with age-related macular degeneration, diabetic eye disease, particularly diabetic maculopathy, uveitis and macular hole amongst the wide range of retinal medical conditions that exist. Jaheed Khan is available at Clinica London on Mondays and selected Tuesdays, while Professor Michel Michaelides sees patients at Clinica London on Thursdays.